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Abstract
Background: Ischemic heart disease is a leading cause of mortality. To study this disease, ischemia/reperfusion (I/R) models
are widely used to mimic the process of transient blockage and subsequent recovery of cardiac coronary blood supply. We
aimed to determine whether the presence of the growth hormone secretagogues, ghrelin and hexarelin, would protect/
improve the function of heart from I/R injury and to examine the underlying mechanisms.
Methodology/Principal Findings: Isolated hearts from adult male mice underwent 20 min global ischemia and 30 min
reperfusion using a Langendorff apparatus. Ghrelin (10 nM) or hexarelin (1 nM) was introduced into the perfusion system
either 10 min before or after ischemia, termed pre- and post-treatments. In freshly isolated cardiomyocytes from these
hearts, single cell shortening, intracellular calcium ([Ca
2+]i) transients and caffeine-releasable sarcoplasmic reticulum (SR)
Ca
2+ were measured. In addition, RT-PCR and Western blots were used to examine the expression level of GHS receptor type
1a (GHS-R1a), and phosphorylated phospholamban (p-PLB), respectively. Ghrelin and hexarelin pre- or post-treatments
prevented the significant reduction in the cell shortening, [Ca
2+]i transient amplitude and caffeine-releasable SR Ca
2+
content after I/R through recovery of p-PLB. GHS-R1a antagonists, [D-Lys3]-GHRP-6 (200 nM) and BIM28163 (100 nM),
completely blocked the effects of GHS on both cell shortening and [Ca
2+]i transients.
Conclusion/Significance: Through activation of GHS-R1a, ghrelin and hexarelin produced a positive inotropic effect on
ischemic cardiomyocytes and protected them from I/R injury probably by protecting or recovering p-PLB (and therefore SR
Ca
2+ content) to allow the maintenance or recovery of normal cardiac contractility. These observations provide supporting
evidence for the potential therapeutic application of ghrelin and hexarelin in patients with cardiac I/R injury.
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Introduction
Cardiac ischemia is one of the leading causes of mortality in the
world. It is caused by a temporary interruption of blood flow in the
arteries of the heart [1]. The primary clinical therapeutic strategy
for treatment of cardiac ischemia is reperfusion. However,
reperfusion can cause additional injury to the heart [1,2].
Recovery of cardiac function following ischemia is critically
dependent on the time spent under ischemic conditions and
reperfusion [3].
In vitro global and in vivo regional ischemia/reperfusion (I/R)
models have been developed to examine experimentally cardiac
ischemia and subsequent reperfusion of the ischemic heart. The
in vivo regional I/R model mimics atherosclerosis by ligating the
left anterior descending coronary artery. The global I/R model for
in vitro study blocks all perfusion of the heart for a given period.
The latter can be easily implemented and affects a larger area with
a less variability among different regions [4]. It is used to mimic
the process of cardiac arrest and cardiac surgery [5]. This model is
also more appropriate for obtaining isolated cells which have been
through similar ischemia conditions without the regional differ-
ences often observed in regional I/R models.
In the past 50 years, great progress has been made to clarify the
metabolic changes that occur following I/R [1,2,6,7]. During
ischemia, depletion of oxygen and ATP inhibits SR Ca
2+ ATPase
(SERCA2a) and Na
+-K
+ ATPase activities. This results in an
accumulation of intracellular Ca
2+ ([Ca
2+]i) and Na
+ ([Na
+]i)
[1,2,6,7]. The subsequent reintroduction of oxygen during
reperfusion leads to the generation of large amounts of reactive
oxygen species (ROS), causing increased oxidative stress and
subsequent damage to the plasma and SR membranes resulting in
further increases in [Ca
2+]i. The combined effects of ROS and
[Ca
2+]i overload also favor the opening of the mitochondrial
permeability transition pore (mPTP), which induces cardiomyo-
cyte apoptosis and necrosis [1,2,6,7].
Ghrelin is a 28 amino acid peptide produced in the stomach and
is an endogenous ligand of the growth hormone secretagogue
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ghrelin, hexarelin, also binds and activates the GHS-R1a
[9,10,11]. Ghrelin mainly exists in the pituitary and gastrointes-
tinal system [8,12], while the distribution of its receptor GHS-R1a
is ubiquitous and has been confirmed in the myocardium [12,13].
Although ghrelin may bind to receptors other than GHS-R1a
[14,15,16], its main target is GHS-R1a.
Previous studies have confirmed the protective effects of GHS
on whole heart function after I/R. Administration of ghrelin in vitro
to I/R rat hearts was shown to reduce the infarct size [17], and
enhance cardiac function [18] through the activation of PKC [17].
These effects are likely initiated by the binding of ghrelin to its
receptor, GHS-R1a [18]. Further studies in rats pre-treated with
GHS for 7 days in vivo prior to in vitro I/R injury showed an
improvement in cardiac function [10] and attenuation of
myocardial injury and apoptosis through the inhibition of
endoplasmic reticulum (ER) stress [19]. Similarly, hexarelin has
also been shown to play a cardioprotective role in I/R hearts from
rodents [10,17,20].
As discussed above, whole heart functional studies employing
the in vivo and in vitro I/R models have revealed some potential
mechanisms of the cardioprotective effects of GHS. Detailed
cellular and molecular pathways employed by GHS through
activation of GHS-R1a after cardiac I/R remain elusive. Since
[Ca
2+]i plays a critical role in cardiomyocyte contraction and I/R
injury, in this study we investigated the alterations in and
regulation of [Ca
2+]i homeostasis in isolated mouse cardiomyo-
cytes with or without I/R and GHS treatment.
Methods
Animals and Chemicals
All experiments conformed to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health (NIH Publication No.85–23, revised 1996), and the
protocol was approved by the Animal Ethics Committee of the
University of Queensland (AEC # SBMS/814/07/NHMRC). All
surgeries were performed under sodium pentobarbital anesthesia,
and all efforts were made to minimize suffering.
Human ghrelin was obtained from Auspep (Parkville, Australia).
Hexarelin was obtained from GL Biochem (Shanghai, China).
Pentobarbital sodium was purchased from Virbac Pty Ltd
(Australia). Heparin sodium salt was purchased from Sigma
Aldrich (St. Louis, MO, USA). Fura 2-AM was purchased from
Invitrogen (Eugene, Oregon, USA). [D-Lys3]GHRP-6 was
purchased from Anaspec Inc. (San Jose, CA). BIM28163 was
kindly provided by Michael D. Culler (Ipsen Pty Ltd, Australia).
Other chemicals for recording solutions were purchased from
Sigma (St. Louis, MO, USA).
In vitro Ischemia/Reperfusion Model and Preparation of
Ventricular Myocytes
Adult male C57/B1 mice (7 to 9 weeks old) weighing between
34 g and 36 g were anesthetized with sodium pentobarbitone
(40 mg/kg, ip) containing heparin (500 Units, ip). The heart was
rapidly excised, cannulated and perfused retrogradely via the aorta
with Tyrode solution at 3 ml/min on a Langendorff perfusion
apparatus (composition in mM: 10 HEPES, 143 NaCl, 5.4 KCl,
0.5 MgCl2, 10 Glucose, 20 Taurine, 1.5 CaCl2; pH 7.4; bubbled
with 100% O2 at 37uC).
The times for stabilization, ischemia and reperfusion were
similar to previous studies [3], and are generally considered the
most appropriate for functional studies using an in vitro I/R model.
After 20 min of stabilization, the heart was subjected to 20 min of
no-flow global ischemia followed by 30 min of reperfusion.
Control hearts were continuously perfused for 70 min. Ghrelin
(10 nM) or hexarelin (1 nM) was administered in the perfusion
solution before or after ischemia for 10 min [13], termed GHS
pre-treatment and post-treatment respectively. In some experi-
ments, the GHS-R1a antagonist [D-Lys3]-GHRP-6 (200 nM) or
BIM28163 (100 nM) was introduced into the perfusion system
5 min before the onset of ischemia and remained present
throughout (15 min in total).
Following perfusion, cardiomyocytes were isolated from the left
ventricle of each heart with Tyrode solution containing 100 mM
CaCl2, 0.6 mg/ml collagenase Type II (Worthington, NJ, USA)
and 0.1 mg/ml proteinase type XXIV (Sigma, MO, USA). The
Ca
2+ level was gradually increased to 1.5 mM over 30 min. The
yield of this isolation was usually around 60 – 70%. Only
cardiomyocytes that were quiescent with a rod shape, sharp edges
and clear striations were used in this investigation. At least 3 hearts
were used in each group.
Measurement of Sarcomere Shortening
Sarcomere shortening was measured as previously described
[21]. In brief, cardiomyocytes were electrically stimulated at
0.5 Hz until contractions became uniform. Following this, 10 – 20
consecutive contractions were recorded. The percentage of
sarcomere shortening, time-to-peak shortening and time-to-90%
relaxation were determined by IonWizard software (IonOptix
Corporation, MA).
Measurement of Intracellular Ca
2+ Transients and SR Ca
2+
Content
The isolated and Ca
2+-tolerant cardiomyocytes were loaded
with 5 mM Fura-2 AM (Invitrogen, CA, USA) for 10 min at room
temperature. Cardiomyocytes were observed through a Nikon
fluor 640 oil immersion objective and positioned for recording of
Fura-2 fluorescence signals. During field stimulation at 0.5 Hz,
cytoplasmic Fura-2 was excited by an IonOptix Hyperswitch dual-
excitation light source (IonOptix Corporation, MA) at 340 and
380 nm and emitted light collected in a photomultiplier tube.
[Ca
2+]i concentration was inferred from the ratio (R) of the
intensity of the emitted fluorescence signals. Amplitude, time-to-
peak, time-to-90% decay, and rate of rise (dR/dt) of the derived
[Ca
2+]i transients were determined by IonWizard software.
For estimation of SR Ca
2+ content, cardiomyocytes with
cytoplasmic Fura-2 were paced at least 15 times at 0.5 Hz and
then stopped. About 30s later, 10 mM caffeine was added to
induce SR Ca
2+ release. The area under the caffeine-induced
[Ca
2+]i transient (area under curve, AUC) and its amplitude were
used as a reflection of the SR Ca
2+ content [22]. Time-to-90%
decay of caffeine-induced increase in [Ca
2+]i was also measured to
estimate the Ca
2+ clearance ability of Na
+-Ca
2+ exchanger (NCX).
RT–PCR
Total cellular RNA was extracted from left ventricle, septum
and right ventricle of mouse hearts using a TRIzol Plus RNA
Purification kit (Invitrogen, CA, USA). Single-stranded cDNA was
synthesized from 2 mg total RNA with an iScript cDNA Synthesis
kit (Bio-Rad Laboratories, CA, USA) following the manufacturer’s
instructions.
PCR was performed using JumpStart Taq DNA polymerase
(Sigma, MO, USA), the cDNA generated above and the
corresponding primers for GHS-R1a [23] (Forward: TCATC-
GATCACAGCCATGT; Reverse: AAGCCAAACTGAC-
CATGT; Tm = 64uC, 40 cycles). Mouse 18s rRNA was
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and pituitary were chosen as negative and positive controls
respectively for GHS-R1a. PCR products were separated by
agarose gel electrophoresis (2%), stained with ethidium bromide
and visualized under UV light.
Western Blotting
Protein expression of the GHS receptor GHS-R1a and the
phosphorylated phospholamban (p-PLB)/phospholamban (PLB)
that are essential for SERCA2a activity were examined by
Western blot analysis according to previous reports [24,25]. In
brief, proteins were extracted from isolated cardiomyocytes (GHS-
R1a) or minced mouse left ventricles (p-PLB and PLB) in lysis
buffer. Extracted proteins (100 mg) were denatured at 37uC for
30 min (p-PLB and PLB) or 70uC for 10 min (GHS-R1a) in 26
sample buffer, separated on 10–15% SDS-polyacrylamide gels and
transferred to nitrocellulose membranes. After blocking, the
membrane was incubated with polyclonal rabbit anti- mouse
phospholamban (phospho S16,1:1000; abcam, Cambridge, MA,
USA), polyclonal rabbit anti- mouse phospholamban (1:1000;
abcam) or polyclonal goat anti-human GHS-R1a (1:1000; Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA) primary
antibodies overnight at 4uC before incubation with the corre-
sponding secondary antibodies (1:5000) and detection with
enhanced chemiluminescence (Pierce) according to the manufac-
turer’s instructions. Mouse GAPDH (1:2000; Milipore, Billerica,
MA, USA) was used as the internal control to allow semi-
quantitative densitometry analysis on scanned films using ImageJ
software [24].
Statistical Analysis
All data were expressed as mean 6 S.E.M. One-way ANOVA
with Tukey post hoc test was carried out for multiple comparisons as
appropriate. In all comparisons, the differences were considered to
be statistically significant at a value of P , 0.05.
Results
GHS-R1a Expression in Mouse Heart
The mRNA and protein expression of GHS-R1a, a GHS
receptor in the mouse heart, was examined by RT-PCR and
Western blots. As shown in FIG.1, GHS-R1a mRNA and protein
is distributed in different regions of mouse heart, including left
ventricle, septum and right ventricle. However, the protein
expression level was relatively low compared to the breast cancer
cell line used as positive control [24].
Effect of Ghrelin and Hexarelin on Sarcomere Shortening
and Intracellular Ca
2+ Transients after I/R
To determine the effects of ghrelin and hexarelin on
cardiomyocyte function after I/R, cell shortening (FIG. 2A and
E) and [Ca
2+]i transients (FIG. 3A and 3F) were recorded during
stimulation at 0.5 Hz.
Sarcomere shortening was expressed as percentage of the
resting sarcomere length (FIG. 2). It was found that relative
sarcomere shortening was significantly reduced after I/R.
However, the presence of 10 nM ghrelin or 1 nM hexarelin
during pre- and post-treatments protected cardiomyocytes against
this negative effect of I/R (FIG. 2B and F). The amplitude of the
corresponding [Ca
2+]i transients decreased in the I/R group, as
determined by the cytoplasmic fura-2 ratio changes shown in
FIG. 3. Again, GHS treatment showed protective effects in
cardiomyocytes against I/R-induced reductions in [Ca
2+]i tran-
sients (FIG. 3).
Basal [Ca
2+]i levels were significantly increased after 20 min
ischemia (control vs ischemia: 1.63 6 0.03, n = 72 cells vs 1.80 6
0.05, n = 80 cells; P , 0.01), which is consistent with previous
reports describing increased cytoplasmic Ca
2+ and possible Ca
2+
overload after ischemia [1,2]. The increased basal [Ca
2+]i after I/
R was not reversed by either ghrelin pre- (1.99 6 0.04, n = 90
cells, P , 0.05) and post-treatment (2.23 6 0.05, n = 103 cells, P
, 0.001), or hexarelin pre- (2.24 6 0.05, n = 63 cells, P , 0.001)
and post-treatment (2.20 6 0.06, n = 66 cells, P , 0.001).
GHS treatment also influenced the time course of sarcomere
shortening (FIG. 2) and [Ca
2+]i transients after I/R (FIG. 3). First,
ghrelin post-treatment (FIG. 2C) and hexarelin pre-treatment
(FIG. 2G) further prolonged the increased time-to-peak shortening
following I/R. In addition, the corresponding time-to-peak of
[Ca
2+]i transients in the ischemic group was also delayed by
hexarelin pre-treatment (FIG. 3H). Furthermore, the time-to-90%
decay of the [Ca
2+]i transients after GHS treatments (FIG. 3D and
I) was similar to that in the ischemic group without GHS
treatment, but nearly all GHS treatments except ghrelin pre-
treatment (FIG. 2D and H) shortened the time-to-90% relaxation
of the force compared to the I/R group. This indicates a lusitropic
effect of GHS. As shown in FIG. 3E and J, the decrease in the
rising rates of [Ca
2+]i transients after I/R was also diminished by
all GHS treatments, which may indicate the effect of GHS on
Ca
2+ influx through L type Ca
2+ current (ICaL), Ca
2+ release from
SR through ryanodine receptors (RyR2s) or both.
Effect of Ghrelin and Hexarelin on SR Ca
2+ Content after
I/R
A possible explanation for the decrease in the [Ca
2+]i transient
amplitude (FIG. 3B and G) and the rate of increase in dR/dt of
Ca
2+ transients (FIG. 3E and J) after I/R may be a consequence of
reductions in SR Ca
2+ content [22,26]. In order to estimate the
SR Ca
2+ content, we used caffeine (10 mM) to activate RyR2s and
thoroughly deplete the SR, resulting in a significant rise in [Ca
2+]i
(see the details in Methods and FIG. 4A [27]). The amplitude of
caffeine-induced [Ca
2+]i transients and area under the transient
curve can be used as estimates of the amount of Ca
2+ stored in the
SR [22]. Prior to caffeine application, cells were stimulated at
0.5Hz for 30s to normalize and replenish the SR Ca
2+ content
[22]. As shown in FIG.4B and C, there was a reduction in SR
Ca
2+ content after I/R that was restored by all GHS treatments.
To confirm whether GHS has an effect on the SR Ca
2+ content
of normal cardiomyocytes without ischemia, we performed ghrelin
post-treatment on control hearts. We selected ghrelin post-
treatment because it was the most effective at increasing SR
Ca
2+ content in I/R cardiomyocytes. The results (FIG. 4B and C)
show no significant differences in area under the curve and
amplitude of caffeine-induced Ca
2+ transients between the control
and ghrelin post-treated non-ischemic cardiomyocytes.
The time-to-90% decay of caffeine-induced Ca
2+ transients
mainly reflects the Ca
2+ clearance ability of the NCX with a lesser
contribution of sarcolemmal Ca
2+ ATPase and mitochondrial
uniporter [28], as the function of SERCA2a was counteracted by
the opening of RyR2 in the presence of caffeine. As shown in
FIG. 4D, the shortened time-to-90% decay of caffeine-induced
Ca
2+ transients after I/R indicates an accelerated Ca
2+ clearance
by the NCX. Therefore, this may suggest exaggerated NCX
activity after I/R. GHS treatment prevented the reduction in the
time-to-90% decay of caffeine-induced Ca
2+ transients after I/R,
which may suggest a normalization of NCX activity.
In order to further confirm whether these changes in the SR
Ca
2+ store were partially due to alterations in the uptake of Ca
2+
into SR, the protein expression level of p-PLB and total PLB were
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ylated form p-PLB have opposing effects on SERCA2a, as PLB
inhibits SERCA2a activity and p-PLB releases this inhibition [28].
As shown in FIG. 4F, a significant decrease in p-PLB/PLB ratio
after I/R was reversed by GHS treatment. This change
corresponds with the recovery of SERCA2a activity after I/R by
all GHS treatments. Taken together, these results further support
our assertion that the protective effect of ghrelin on Ca
2+ transients
was achieved at least in part by the recovery of SERCA2a activity
and SR Ca
2+ content.
GHS-R1a Mediates the Cardioprotective Effect of GHS
To investigate whether the GHS-induced effect on cardiomyo-
cytes exposed to I/R injury was mediated by GHS receptors, we
tested the GHS-R1a antagonists [D-Lys3]-GHRP-6 and
BIM28163 [29,30] in ghrelin and hexarelin post-treatment groups.
[D- Lys3]-GHRP-6 (200 nM) or BIM28163 (100 nM) was
introduced into the perfusion system 5 min before GHS post-
treatment for a total of 15 min. Alone, neither of these antagonists
showed any effect on the sarcomere shortening or [Ca
2+]i
transients. However, both antagonists completely blocked the
protective effects of ghrelin and hexarelin on sarcomere shortening
(FIG. 5A) and [Ca
2+]i transients (FIG. 5B). These observations
suggest that the protective effect of GHS is mediated by the GHS-
R1a.
Discussion
In the present study, we have confirmed that reduced cell
shortening in mouse cardiomyocytes exposed to in vitro I/R injury
is attributable to a reduction in both the amplitude and rising rate
of [Ca
2+]i transients, which may be due to a reduced SR Ca
2+
content caused by decreased SERCA2a activity. We have also
demonstrated for the first time that GHS such as ghrelin and
hexarelin, produce a protective effect on cardiomyocytes exposed
to in vitro I/R injury. Normal cardiac myocyte contractility was
maintained by a normal amplitude and rising rate of [Ca
2+]i
transients after GHS treatment, which may be attributed to
normalized SERCA2a activity and SR Ca
2+content.
The mechanisms underlying cardiac ischemia are multifaceted,
including ATP depletion, ROS generation, [Ca
2+]i overload
amongst others. The disruption of Ca
2+ homeostasis can cause
inappropriate activation of Ca
2+ dependent proteases and
phospholipases essential for various cardiac functions, which
may lead to further damage of the cardiomyocytes [2]. A tighter
regulation of Ca
2+ might therefore be an effective way to protect
cardiomyocytes from I/R injury [6,7].
As shown in our study, reduced heart function after I/R exists at
the single cell level, as reflected by reduced cardiomyocyte
contractility (FIG. 2) accompanied by a decrease in the [Ca
2+]i
transient amplitude (FIG. 3) and an increase in the basal [Ca
2+]i
(details in Results). In addition, the prolonged time for maximal
sarcomere shortening after I/R (FIG. 2C and G) with unchanged
time-to-peak Ca
2+ transients (FIG. 3C and H) may reflect
impairment of the contractile machinery essential for cell
contraction, such as the degradation of the regulatory protein
troponin [31]. Moreover, the reduction observed in the amplitude
(FIG. 3B and G) and rising rate of [Ca
2+]i transients after I/R
(FIG. 3E and J) could be due to decreases in voltage-gated L type
Ca
2+ current (ICaL) [32], SR Ca
2+ content (FIG. 4B and C) or
Figure 1. mRNA (A) and protein (B and C) expression of GHS-R1a in mouse heart. (A) Liver (L) and pituitary gland (P) were used as the
negative and positive controls respectively. Mouse 18s rRNA was chosen as an internal control. (B) A breast cancer (BC) cell line was used as the
positive control. (C) n = 3 for Western blots, data are shown as means 6 S.E.M. and analyzed by One-way ANOVA with Tukey’s post hoc test. ***P ,
0.001 vs BC group. GHS-R1a mRNA and protein are expressed in the left ventricle (LV), septum (S) and right ventricle (RV) of the mouse heart.
doi:10.1371/journal.pone.0035265.g001
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the SR Ca
2+ release and subsequently alter the shortening phase of
contraction. Our results certainly support the concept of a re-
duction in SR Ca
2+ loading ability. This is shown by the reduced
caffeine-inducedCa
2+transients,thereductionintheratioofp-PLB
tototalPLBattheproteinlevelandthereforethereducedactivityof
SERCA2a (FIG. 4). The reduced activity of SERCA2a is
indicated by our data where we compared the time-to-90%
decay of [Ca
2+]i transients under normal twitch with the time-
to-90% decay of caffeine-induced Ca
2+ transients. Under
normal twitch, there was no significant difference in the time-
to-90% decay of Ca
2+ transients among experimental groups
(FIG. 3D and I), however, the time-to-90% decay of caffeine-
induced Ca
2+ transients was shortened in ischemic group
(FIG. 4D). Taken together, this suggests increased NCX activity
but decreased SERCA2a activity after IR, with the decreased
SERCA2a activity contributing to the decreased SR Ca
2+
content. Nevertheless, the reduction in SR Ca
2+ content may
also be caused by an increase in the RyR2s-dependent and -
independent Ca
2+ leak from SR, as reported in cardiomyocytes
from the failing rabbit heart [33].
A previous study from our laboratory has found that ghrelin and
hexarelin exert a positive inotropic effect on normally perfused rat
hearts [34] and isolated adult rat ventricular cardiomyocytes [21]
through GHS-R1a [34], the reported functional receptor for
GHS. This study also demonstrated that ghrelin and hexarelin
pre- or post-treatments exert a protective effect on adult mouse
ventricular cardiomyocytes during in vitro I/R injury via a positive
Figure 2. Effects of GHS on the contractile properties of mouse cardiomyocytes exposed to ischemia/reperfusion. (A) and (E) are
representative superimposed traces of sarcomere shortening after ghrelin (G) or hexarelin (H) pre-treatment (pre) and post-treatment (post). Both
hexarelin and ghrelin improved the reduction in sarcomere shortening (B and F), but not the prolonged time-to-peak shortening (C and G). The time-
to-peak shortening was further prolonged in G post- and H pre-treatment groups. The time for relaxation (D and H) was shortened in G post-, H pre-
and post-treatment groups. n = 99, 84, 84, 95, 106 and 100 cells/3 mice in control, ischemia, G pre, G post, H pre and H post groups, respectively.
Data are shown as means 6 S.E.M. and analyzed by One-way ANOVA with Tukey’s post hoc test. *P , 0.05, ** P , 0.01, *** P , 0.001 vs ischemic
group.
doi:10.1371/journal.pone.0035265.g002
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consistent with those from previous studies using whole heart after
I/R. Administrations of 20 nM ghrelin/1 mM hexarelin by
Frascarelli et al. [17] or 0.1 nM-10 nM ghrelin by Chang et al.
[18] protected the in vitro I/R rat heart from a reduction in cardiac
function. Treatment with 320 mg/kg ghrelin or 80 mg/kg
hexarelin (daily for 7 days) [10], or 10 nM/kg ghrelin (2 doses
12 h apart, the hearts were removed 1h after the last dose) [19]
prevented I/R injury in the isolated rat heart by ameliorating the
damaged heart function and attenuating the myocardial apoptosis.
It has been suggested that ghrelin and hexarelin may exert their
protective effects on rat heart I/R models through the activation of
protein kinase C (PKC) [17] and/or inhibition of ER stress [19].
For the first time, we have demonstrated that the positive
inotropic effect of GHS is at least partially due to the recovery or
maintenance of normal SERCA2a activity (FIG. 4E and F) and
therefore normal SR Ca
2+ content (FIG. 4B and C). This is
supported by the increased p-PLB/PLB protein ratio (FIG. 4F)
after GHS treatment. Furthermore, when comparing the time-to-
90% decay of [Ca
2+]i transients under normal twitch (FIG. 3D
and I) and the time-to-90% decay of caffeine-induced Ca
2+
transients (FIG. 4D), it suggests that SERCA2a activity was
recovered after GHS treatment since the time-to-90% decay of
caffeine-induced Ca
2+ transients was restored back to control
levels (normalization of NCX) by GHS treatment, whereas the
time-to-90% decay of [Ca
2+]i transients under normal twitch had
no significant change.
Ca
2+ overload, which has been reported as the main damaging
factor causing cardiac dysfunction after ischemia [2], was also
observed in this study (see results for details). The basal level of
[Ca
2+]i was increased in ischemic cells with or without GHS
treatment. The basal level of [Ca
2+]i would reflect the activity of
both SERCA2a and RyR2s [35]. Following the recovery of
SERCA2a activity by GHS treatment (FIG. 4F), SR Ca
2+ content
was also restored. If the sensitivity of RyR2s to Ca
2+ is changed in
ischemia (Ca
2+ leak from SR), increased Ca
2+ leak from SR may
occur. Such a presumption seems consistent with an even greater
increase in the basal level of [Ca
2+]i after GHS treatment.
Moreover, the increased basal [Ca
2+]i in GHS treated groups may
also be due to the increased Ca
2+ influx into the cell through
ICaL,which has been reported previously by our group [21]. To
what extent this effect contributes to the improvements in Ca
2+
homeostasis and cardiomyocyte function seen in the current study
requires further investigation.
Figure 3. Effects of GHS on [Ca
2+]i transients in cardiomyocytes exposed to ischemia?reperfusion. (A) and (F) are representative
superimposed traces of [Ca
2+]i transient after ghrelin (G) or hexarelin (H) pre-treatment (pre) and post-treatments (post). R represents the emission
fluorescence ratio of fura-2 from excitation at 340 and 380nm, and Ru represents the ratio unit. Both hexarelin and ghrelin improved the reduced
amplitude of [Ca
2+]i transients (B and G). The time-to-peak fluorescence was prolonged in ghrelin and hexarelin pre-treatment (C and H) groups, but
the decreased rate of rise of [Ca
2+]i transients after ischemia was reversed to control level by all H and G pre- and post-treatments (E and J). Ghrelin
and hexarelin had no effect on the time-to-90% decay of [Ca
2+]i transient (D and I). n = 72, 80, 90, 103, 63 and 66 cells/3 mice in control, ischemia, G
pre, G post, H pre and H post groups, respectively. Data are shown as means 6 S.E.M. and analyzed by One-way ANOVA with Tukey’s post hoc
test. *P , 0.05, **P , 0.01, *** P , 0.001 vs ischemic group.
doi:10.1371/journal.pone.0035265.g003
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PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35265Figure 4. Effects of GHS on sarcoplasmic reticulum (SR) Ca
2+ content and phospho-phospholamban (p-PLB)/phospholamban (PLB)
expression. (A) Illustration of the SR Ca
2+ content measurement protocol (data from cardiomyocytes exposed to ischemia/reperfusion). R represents
the emission fluorescence ratio of fura-2 from excitation at 340 and 380nm. Cardiomyocytes were perfused with Tyrode solution containing 1.5 mM
CaCl2 and paced at 0.5 Hz for at least 30 s. 10 mM caffeine was then added to induce SR Ca
2+ release. SR Ca
2+ content, as determined by both (B)
Area under curve and (C) amplitude of the caffeine-induced Ca
2+ release, significantly decreased after 20 min ischemia compared with the control
group. Ghrelin (G) or hexarelin (H) pre-treatment (pre) and post-treatment (post) significantly increased the SR Ca
2+ content after 20 min ischemia (B
and C), but introduction of ghrelin into the perfusion system at 40 min and lasting for 10 min (G post control) had no effect on the SR Ca
2+ content of
the cells isolated from the normal perfused heart. (D) The time-to-90% decay of caffeine-induced increases in [Ca
2+]i mainly reflect the Ca
2+ clearance
ability of the Na
+/Ca
2+ exchanger (NCX). n = 18, 44, 44, 33, 38, 41 and 38 cells/3 mice in G post control, control, ischemia, G pre, G post, H pre and H
post, respectively. (E) Representative western blots of the total phospholamban (PLB) and the phosphorylated PLB (p-PLB) in 6 groups and (F) the
densitometric quantification of ratio of p-PLB/PLB (expressed as fold increase relative to control). n = 5 mice in each group. Data are shown as means
6 S.E.M. and analyzed by one-way ANOVA with Tukey’s post hoc test. *P , 0.05, **P , 0.01, *** P , 0.001 vs ischemic group.
doi:10.1371/journal.pone.0035265.g004
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35265We show here the expression of GHS-R1a in the mouse heart at
both the mRNA and protein level (FIG.1). In order to determine
whether the protective effect of GHS on cardiomyocytes after I/R
injury was mediated by GHS-R1a, we administrated the GHS-
R1a antagonists [D-Lys3]-GHRP-6 or BIM28163 along with
GHS in I/R hearts. There is no report of non-specific effects of
BIM28163 and [D-Lys3]-GHRP-6, and both reagents are widely
applied as selective GHS-R1a antagonists in different cell types (eg
neurons) [36], organs (stomach, small intestine) [37,38,39], and
species (rodents [36,38], dogs [37]). The GHS-R1a antagonists
alone showed no effect on cardiomyocytes, but completely blocked
the effects of ghrelin or hexarelin on sarcomere shortening and
[Ca
2+]i transients of cardiomyocytes after I/R injury (FIG. 5). This
suggests that the effects of GHS, especially their actions on the
contractile properties of cardiomyocytes and the corresponding
increases in [Ca
2+]i transients, are mediated by GHS-R1a.
In summary, ghrelin and hexarelin pre- and post-treatments
protected mouse cardiomyocytes from in vitro I/R injury and
preserved the cell shortening by regulating [Ca
2+]i. Both ghrelin
and hexarelin prevented the decrease in the amplitude of [Ca
2+]i
transients and SR Ca
2+ content after I/R by maintaining the ratio
of p-PLB to total PLB and therefore the SERCA2a activity. Their
positive inotropic effect on the cardiomyocytes and corresponding
increase in [Ca
2+]i transients is mainly mediated by the activation
of GHS-R1a.
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